Lokelma Approved in China for Adult Patients With Hyperkalaemia

China’s National Medical Products Administration approved AstraZeneca’s Lokelma (sodium zirconium cyclosilicate) for treatment of adult patients with elevated levels of potassium in the blood.

The approval was based on the results of four studies in which patients receiving Lokelma experienced a significant reduction of their blood potassium level.

The drug is approved in the U.S., Canada and the EU for the treatment of the condition. It is undergoing separate regulatory review in Japan, with a decision expected in the first half of 2020.